TSXV:RHT.H - Post by User
Comment by
theinvestor22on Mar 24, 2022 11:51am
121 Views
Post# 34541643
RE:RE:RE:NEWS - New Contract
RE:RE:RE:NEWS - New ContractThis might not be recurring revenue in the conventional sense, but that hardly matters if the deal with this CRO leads to RHT being involved with many new clinical trials every year, so it could level off at some point and not really go down.
Also, with so many doctor's offices being involved, this could lead to a great many new contracts with physicians being signed. So, it might open many doors. Plus, it might open doors to other clinical trial niches.
throwin wrote: lscfa wrote: clinical trials are short term and cancer patients expire so how real is it to suggest this is recurring revenue.
Does Iscfa understand that clinical trials last for years?
Phase 1, Phase 2, Phase 3.
Each phase requires more patients, across many clinics, in multiple cities. Anyone having owned pre- revenue drug companies know how long and intense these trials can be.
Oh, and many, many cancer patients live for years. Chemotherapy, radiation, and recovery from surgery.
Which means being monitored daily. Ever know a loved one who is on chemo?? There are literally a dizzying amount of side effects from these drugs.
Long Reliq!